LY-2624803, also known as HY-10275, is a dual histamine H1 receptor and serotonin 5-HT2A receptor antagonist which was under development for the treatment of insomnia but was never marketed. It is taken orally.
Pharmacology The drug is described as a high-affinity highly selective histamine H1 receptor inverse agonist with additional strong serotonin 5-HT2A receptor antagonism or inverse agonism. The precise balance of these activities has not been disclosed. It was found to dose-dependently increase slow wave sleep in animals. In a phase 2 clinical trial, the drug was found to significantly reduce wake after sleep onset (WASO) (by 35 minutes at 1 mg and by 62 minutes at 3 mg) as well as to reduce sleep onset latency in humans. No next-day residual fatigue was observed. In terms of chemical structure, it is an analogue of tricyclic compounds like quetiapine and amoxapine.
Development LY-2624803 was under development by Eli Lilly and Hypnion. Its development was discontinued in 2011. The drug reached phase 2 trials prior to the discontinuation of its development. Besides doxepin (Silenor; SO-101) and esmirtazapine (ORG-50081), it was one of the only histamine H1 receptor antagonists to have reached phase 2 trials for treatment of insomnia.
See also Serotonin 5-HT2A receptor antagonist List of investigational insomnia drugs
References


